TriangleAcalabrutinib (NCT03516617)
Acalabrutinib trial for Chronic Lymphocytic Leukemia (NCT03516617). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated, asymptomatic early CLL or SLL diagnosed less than 24 months earlier. Complete CLL-IPI risk testing is required.
The idea: high-risk patients receive oral acalabrutinib alone or with intravenous obinutuzumab, by random assignment. Acalabrutinib blocks BTK growth signaling; obinutuzumab targets CD20 on B cells. Low- or intermediate-risk patients undergo observation instead. Patients already needing treatment are excluded.
This phase 2 study plans 120 patients. Sameer Parikh leads at Mayo Clinic, with two recruiting US sites: Scottsdale and Rochester.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.